Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. - Wikidata - awgldk - TriplyDB

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

http://www.wikidata.org/entity/Q36554980

about

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting Modeling HIV vaccine trials of the future.Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol.A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.Nondaily preexposure prophylaxis for HIV prevention.Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence Therapeutic drug monitoring by dried blood spot: progress to date and future directions.Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry.Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.Plasma Tenofovir-levels to Support Adherence to TDF/FTC Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study.Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis.Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.Changes in Kidney Function Associated with Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.

P2860

Q26753097-09F7B5FE-B5A6-4913-8D01-F5863CF5F0CD Q27313352-2972B90D-8C9B-4FEA-BE52-40A5DC9BDFB0 Q28552015-10074B22-FF80-4AFF-ACD1-8F7BADD6CE87 Q30393307-91156B33-9E62-4976-8232-131CE6A00E66 Q33697680-662F5BBB-340C-41C8-A87F-CACAD1E2B061 Q33909720-2DE8F066-0009-4B47-9AE3-5E049BFF15A3 Q34675000-E9CF86E5-283A-4338-AFBA-041062521514 Q34968312-B0FE1557-6019-4738-840C-173A58061110 Q35174468-46637E15-751D-4B30-BEDF-E88402F67894 Q35230243-0AC04A59-D405-4B7E-875A-E8F51A0ABE21 Q35541521-F190C920-D410-4FFC-BB14-488BA18361D7 Q36149022-16B00FC6-FA58-4EA9-966F-3A7A0AFC84FC Q36188725-4244A253-B50F-49A7-A47A-E96113F38A2B Q36609638-4D95ABBF-A938-45E7-B801-D85832EC0238 Q36619482-634B21A8-1B5D-46A6-A441-F56E89332874 Q36669377-0BC7451E-EC27-4791-AD2D-2372A7E3C6BD Q36710299-5E3B3088-1629-4614-8ECC-7E4600729DA5 Q36783183-A58CA863-E2E0-4A7B-9456-B6F1D08F44EF Q37018274-67B84698-7CA5-485D-BB0F-71EEBE8CA1FE Q37114554-E5E025CD-43A4-41CC-8A4F-747DF6FC988F Q37296618-9A3163A1-0EFD-4FB1-AAB0-2FAF1DF0ADBC Q37347434-BEF65EF6-393A-470B-9359-E708B3B80779 Q37358658-F1072F67-4C77-4565-9B2F-BE014607AD20 Q37377643-BE47906D-3676-465E-9875-6CC6A57FE684 Q37418247-9F862A47-FB0A-40A0-8B7E-382173C6835D Q37637073-32D6F538-D959-4F56-A123-9A96E447E73F Q38247481-DD8CC3E7-C593-4FA9-87C6-12CA0BCA785C Q38256679-008BA2B8-C6C0-42B7-995C-15BEDFFA3BBD Q38849874-91F57C09-4024-465E-857D-FA768B2F5636 Q39003651-D12CF7C2-1D00-4243-B786-0B876877C07D Q40049420-5D7D3DB7-9322-49C9-87E6-30D5766350C0 Q40057431-87AB8E7B-F0E0-472A-B496-656E9FBCBED0 Q40072965-02357265-3E95-433B-8D13-F51367FA8FB8 Q40074158-D6DC671F-7D35-4D52-A337-576427EBE26F Q40142676-202230B4-A5D6-4F44-A243-ED66269A4B8E Q40396204-9638CDB6-60AA-436E-84BA-9575D10D00B4 Q40538934-FF967BB9-A770-448D-A28D-0FAD5A294B05 Q41975983-E5DFA411-2EBF-47F9-84D9-9F3AAB5B36D0 Q41989627-14CDA108-0BD3-445F-91B4-C4BB5B844550 Q42408717-3CA81381-A978-4B80-A75A-44C568609C7B

P2860

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

http://www.wikidata.org/entity/Q36554980

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@ast

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@en

type

label

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@ast

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@en

prefLabel

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@ast

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@en

P1433

Q36554980-490EE367-704F-409A-B56C-C3E50B09AF92

P1476

Q36554980-09634BE9-4078-4F14-9B0E-95AF48EE637F

P2093

Q36554980-0153E86D-1157-4EA6-9502-75DAF80CDD1E

Q36554980-029EAC15-0371-4C13-AA45-94A77065EAA9

Q36554980-02BAC9AC-E27D-40F3-808F-144FAFC4E5A9

Q36554980-0B5C095A-7116-4CB5-8C49-E227CB9E64AF

Q36554980-0EB76216-E6DE-42BE-9B54-5E03C8987485

Q36554980-4A3628F5-9769-4805-A6A2-9F94AF35FC05

Q36554980-50A63F3E-5164-4AD6-80E7-D54F0E231AC2

Q36554980-75A33123-D40A-4727-94A8-B52CF793A5F4

Q36554980-D5916431-C256-4399-87F1-2FF834D162F7

Q36554980-DA5EA490-5476-4A7A-85E0-50BB5EA8D7CF

P2860

Q36554980-042E8FEC-E6B8-43F8-90D8-D70A686B7EF7

Q36554980-0CF2C5AC-4B77-4E12-A0FB-981461372145

Q36554980-1E14E937-3DCC-44C9-BDA0-257DA2CC6CE7

Q36554980-287E499D-D00E-4D7D-A082-2FF884B3016A

Q36554980-50773045-6224-4955-B856-4E1E5FB396C0

Q36554980-50DF3B1D-17D6-4D1F-ADF0-3358F7AEBF72

Q36554980-521DD326-77F4-4D15-8954-BE5AD818C9AB

Q36554980-5D1DB887-68F6-487C-B35E-56AD215A0296

Q36554980-6355B224-9664-418C-8776-7225C627649F

Q36554980-67BFACB6-9ACA-487E-A909-E038C8022C3A

P304

Q36554980-9FAC2C56-02AB-4DC2-B8F5-EFBB39E66EEB

P31

Q36554980-03162A2D-9152-40FF-BDD8-D41129B44D51

P356

Q36554980-A72C83AA-BEDA-46FC-8664-F62C6FA88FE0

P433

Q36554980-B1EAC6C3-E9B1-4ACE-8C90-F4E1F57097E2

P478

Q36554980-EAC5D289-CE32-4A38-9911-02E4FB4402BF

P577

Q36554980-B0E2B440-B473-48D8-A81F-1B64546FB4BF

P698

Q36554980-4928A947-03B8-49A5-B4EF-EB71753B2ABC

P921

Q36554980-5538A3F2-F894-4171-A3B1-3CA0205F60C7

P932

Q36554980-A03BB791-0AB7-4343-936D-04A19FF63238

P356

P1433

AIDS Research and Human Retroviruses

P1476

Tenofovir, emtricitabine, and ...... and cumulative drug exposure.

@en

P2093

Amie Meditz

http://www.w3.org/2001/XMLSchema#string

Caitlin Fernandez

http://www.w3.org/2001/XMLSchema#string

Edward M Gardner

http://www.w3.org/2001/XMLSchema#string

Jacob Langness

http://www.w3.org/2001/XMLSchema#string

Jennifer J Kiser

http://www.w3.org/2001/XMLSchema#string

Jia-Hua Zheng

http://www.w3.org/2001/XMLSchema#string

Jose R Castillo-Mancilla

http://www.w3.org/2001/XMLSchema#string

Joseph E Rower

http://www.w3.org/2001/XMLSchema#string

Julie Predhomme

http://www.w3.org/2001/XMLSchema#string

Lane R Bushman

http://www.w3.org/2001/XMLSchema#string

P2860

HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Prevention of HIV-1 infection with early antiretroviral therapy

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots

Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.

Clinical evaluation of a dried blood spot assay for atazanavir

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection

P304

384-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/AID.2012.0089

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22935078

http://www.w3.org/2001/XMLSchema#string

P921

P932

3552442

http://www.w3.org/2001/XMLSchema#string